Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
暂无分享,去创建一个
L. Grochow | R. Donehower | S. Kaufmann | Y. Cheng | A. Adjei | S. Gore | E. Rowinsky | R. Jones | P. J. Burke | Y. Cheng | Philip J. Burke | S H Kaufmann | Ross C. Donehower | Steven D. Gore | Richard J. Jones | Yung-Chi Cheng
[1] M. Potměšil,et al. Camptothecins: from bench research to hospital wards. , 1994, Cancer research.
[2] L. Zwelling,et al. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia , 1994 .
[3] J. Mohler,et al. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. , 1994, Cancer research.
[4] L. Liu,et al. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. , 1993, Cancer research.
[5] J. Hwang,et al. Increased synthesis and degradation of DNA topoisomerase I during the initial phase of human T lymphocyte proliferation. , 1993, The Journal of biological chemistry.
[6] L. Zwelling,et al. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia , 1993 .
[7] E K Rowinsky,et al. The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.
[8] P. Hérait,et al. CPT-11-induced cholinergic effects in cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Y. Cheng,et al. Characterization of camptothecin-resistant Chinese hamster lung cells. , 1992, Biochemical pharmacology.
[10] L. Grochow,et al. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. , 1992, Cancer research.
[11] L. Grochow,et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Y. Pommier,et al. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. , 1992, European journal of cancer.
[13] Y. Miura,et al. Effects of CPT‐11 in combination with other anti‐cancer agents in culture , 1992, International journal of cancer.
[14] M. Fukuoka,et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. , 1991, Journal of the National Cancer Institute.
[15] L. Liu,et al. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. , 1991, Cancer research.
[16] S. Kaufmann,et al. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. , 1991, Cancer research.
[17] J. Boehm,et al. Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity , 1991 .
[18] C. Bloomfield,et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] B. Zehnbauer,et al. In vitro evaluation of combination drug purging for autologous bone marrow transplantation. , 1990, Bone marrow transplantation.
[20] S. Howell,et al. Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. , 1990, European journal of cancer.
[21] L. Liu,et al. DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. , 1989, Science.
[22] K. Kohn,et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. , 1989, Cancer research.
[23] R. Sternglanz,et al. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. , 1988, Molecular pharmacology.
[24] L. Liu,et al. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. , 1988, Cancer research.
[25] L. Liu,et al. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.
[26] R. Hertzberg,et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.
[27] M. Muller,et al. Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. , 1985, The EMBO journal.
[28] H. Gralnick,et al. The Morphological Classification of Acute Lymphoblastic Leukaemia: Concordance among Observers and Clinical Correlations , 1981, British journal of haematology.